Skip to the main content.

Outcome-Driven Solutions for Medtech Challenges

Breakthrough innovation requires more than great solutions; it demands deep expertise and insight. Veranex packages outcome-driven solutions with 25+ years of specialized knowledge across major medtech categories, delivering integrated capabilities that solve your most pressing challenges faster and with greater certainty.

Purpose-built solutions. Proven results. User & Patient-centered innovation.

 

Purpose-Built for Breakthroughs

Whether you're transforming patient care or disrupting entire therapeutic categories, innovation requires more than great science, it demands velocity.  Veranex was founded to bridge the gap between visionary concepts and market reality, combining proven expertise with agile execution to accelerate the innovations that matter most.  

We are the Innovation CRO.

Legacy of excellence. Proven execution. Patient impact accelerated.

 

Gary Keeler

1 min read

China Aims to Complete Transition to DRG Payment Model for Inpatient Care by 2024

In November 2021, the Chinese government announced its 3-year (2022-2024) payment reform plan with the end goal to fully implement a diagnosis related group (DRG) payment model for inpatient care. Under the government’s 3-year plan, a specific...

Read More

2 min read

NCCN 2021 Conference Highlights: Elevating Racial Equity in Cancer Care

The National Comprehensive Cancer Network (NCCN) 2021 Annual Conference convened virtually March 18-20, drawing attendees from more than 40 countries...

Read More

4 min read

Is China a 300 Million or 1.4 Billion Healthcare Population Market?

A reflection on the 2019 capability development progress report of the county hospitals in China The Veranex (formerly Boston Healthcare Associates)...

Read More

1 min read

Veranex Partners with Alcon to Conduct Real-World Study Highlighting Efficiencies of Optical Biometer in Cataract Surgery

Alcon, a global leader in eye care, collaborated with Veranex (formerly Boston Healthcare Associates) to conduct a Time-and-Motion Study to support...

Read More

4 min read

Analysis of China’s First National Tender on Coronary Stents

In previous newsletters (Aggressive National Programs To Drive Down Drug Costs, published in January 2019 and Medical Disposables & Consumables...

Read More

4 min read

An Overview of Digital Health in China

We recently discussed the challenges and opportunities for diagnostic players amidst and post- the COVID-19 chaos in the context of China’s health...

Read More

2 min read

FDA Releases Final Guidance on Oncology Therapeutic Class Labeling of Companion Diagnostics

April 2020 On April 13th, 2020, The Food and Drug Administration (FDA) published a final guidance entitled “Developing and Labeling In vitro...

Read More

1 min read

The VALID and VITAL Acts: What Do They Mean for Diagnostic Innovators?

In early March, lawmakers in the U.S. House of Representative and U.S. Senate introduced the Verifying Accurate, Leading-edge IVCT Development ACT,...

Read More

1 min read

German Draft Executive Order Provides Clarity for Reimbursement of Health Apps

Towards the end of 2019, the German Federal Parliament introduced a simplified process for approval and reimbursement of digital health apps...

Read More